Albiglutide Effective in Triple Therapy for Uncontrolled Type 2 Diabetes

March 16, 2015

In obese patients with type 2 diabetes uncontrolled by lifestyle and two oral agents, albiglutide significantly lowered A1c as part of 3-drug therapy.

HARMONY is the global phase 3 clinical trial program for albiglutide (Tanzeum), a GLP-1 receptor agonist administered once weekly by injection. HARMONY 5 evaluated the efficacy and tolerability of albiglutide in obese patients with type 2 diabetes uncontrolled on lifestyle measures and 2 oral medications. Highlights and results in the 8 slides above.